Alteogen Temporarily Suspends Application to Transfer to KOSPI Market… Maintains KOSDAQ Listing

Alteogen (196170), a biopharmaceutical company, decided to temporarily suspend its application for transfer to the KOSPI market and announced it on the 16th. At the shareholder meeting held on December 8, 2025, Alteogen resolved to conditionally delist from the KOSDAQ market and pursue a transfer to the KOSPI market. This decision follows a comprehensive review of recent capital market changes and government/KOSDAQ initiatives aimed at revitalizing the KOSDAQ market. The decision date is July 16, 2026. Alteogen will temporarily maintain its KOSDAQ listing, as the resolution is deemed to better align with enhancing corporate value and maximizing shareholder benefits. While not abandoning the KOSPI transfer plan, the company plans to reassess the feasibility and timing of the transfer based on future corporate value and shareholder benefit potential, with further disclosures required under applicable regulations. Shareholder meeting records from November 6, 2025, and the December 8, 2025, shareholder meeting results were also disclosed. As of Alteogen's December 2025 financials, total assets amounted to 698.7 billion won, liabilities at 244.3 billion won, and equity at 454.4 billion won. Revenue reached 215.9 billion won, operating profit at 106.9 billion won, and net profit at 145.2 billion won. Alteogen, listed on the KOSDAQ market since December 2014, operates in the field of natural science and engineering R&D. According to stock market data, Alteogen's stock price closed at 276,500 won on July 16, 2026, at 16:10, down 12,000 won (-4.16%) from the previous day.